Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168656 | 0.80 | NPC1 (0.48) | KMT2AALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL3804958 | 0.77 | LMNA (0.54) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13168589 | 0.77 | LMNA (0.54) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14353095 | 0.75 | NPC1 (0.55) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL14353097 | 0.75 | NPC1 (0.55) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL22256459 | 0.73 | MEN1 (0.55) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20153332 | 0.72 | ALDH1A1 (0.52) | KMT2AALDH1A1POLBLMNAHCAR2 | |
| SCHEMBL10762861 | 0.72 | ALDH1A1 (0.56) | KMT2AALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL25586848 | 0.72 | ALDH1A1 (0.56) | KMT2AALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL26342343 | 0.72 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2208722-A1 | PROCESS FOR PRODUCTION OF DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALYST, PROCESS FOR PRODUCTION OF -AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE SALT | National University Corporation Nagoya University (JP) | 2010-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | MGAT2, MPST, MGAT1 | KMT2A 53/4885MEN1 1250/4885ALDH1A1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.